[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"wrinkle\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:wrinkle":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,43,73,102,131,155,183,208,237,258,278,301],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100550561","phase-4-head-to-head-comparison-of-all-botulinum-neurotoxin-type-a-products-for-glabellar-rhytides-100550561",false,"NCT06448676","Head-to-Head Comparison of All Botulinum Neurotoxin Type A Products for Glabellar Rhytides","Head-to-Head Comparison of the Efficacy and Safety of All Five Commercially Available Botulinum Neurotoxin Type A Products for the Treatment of Glabellar Rhytides: A Multicenter, Double-Blind, Randomized Controlled Trial","Inclusion Criteria:\n\n* Women aged 18 years or over, with moderate to severe glabellar lines\n* Willing to provide written informed consent\n* American Society of Anesthesiologists (ASA) Physical Status Classification 1 or 2\n* Negative pregnancy test\n\nExclusion Criteria:\n\n* ASA Classification 3 or over\n* History of hypersensitivity or adverse reactions to botulinum toxin or any of its components\n* Infection at the injection site\n* Previous treatment with botulinum toxin (lifetime)\n* Pregnant or breastfeeding women\n* Neuromuscular disorders or conditions that could interfere with the study assessments",true,"FEMALE","18 Years",{"count":20,"type":21},325,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Study Type: This is a multicenter, triple-blind, randomized controlled trial.\n\nPurpose: The goal of this clinical trial is to compare the effectiveness and safety of all commercially available Botulinum Neurotoxin Type A (BoNT-A) products for treating glabellar rhytides, commonly known as frown lines. This study is designed to provide comprehensive data on how these treatments compare in terms of improving frown lines and the duration of their effects.\n\nMain Questions the Study Aims to Answer:\n\nWhich BoNT-A product provides the longest lasting effect on reducing glabellar rhytides? How do these products compare in terms of safety and the occurrence of side effects?\n\nParticipant Tasks:\n\nWomen aged 18 years or older with moderate to severe glabellar lines will participate.\n\nParticipants will receive injections of a BoNT-A product into specific facial muscles.\n\nThey will need to take weekly photographs using their smartphones to document changes in their frown lines.\n\nThese photos will be securely sent to our research team for analysis. Participants will complete questionnaires at the start and end of the study to assess their satisfaction, quality of life, and any changes in their condition.\n\nComparison Group:\n\nResearchers will compare participants receiving different types of BoNT-A products to see which one is more effective at reducing frown lines and maintaining these effects over time.\n\nThe safety profiles of these products will also be compared to determine which has the fewest and least severe side effects.\n\nThis study aims to fill important gaps in our understanding of Botulinum Neurotoxin Type A treatments, guiding more effective clinical decisions and improving patient outcomes.",[27,28,29],"Wrinkle","Glabellar Frown Lines","Glabellar Furrowing","RECRUITING","2026-06-30",{"date":33,"type":34},"2026-07-02","ACTUAL",{"date":36,"type":34},"2026-02-02",{"date":38,"type":21},"2027-02-01",{"name":40,"class":41},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","OTHER",3,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":16,"sex":17,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":42},"100618404","evaluation-of-performance-and-safety-of-innea-and-innea-aqua-for-the-treatment-of-cheek-and-dcolletage-wrinkles-100618404","NCT07331181","Evaluation of Performance and Safety of INNEA and INNEA AQUA for the Treatment of Cheek and décolletage Wrinkles","A Post-Market, Single-arm, Confirmatory Interventional Clinical Investigation to Evaluate the Performance and Safety of INNEA and INNEA AQUA for the Treatment of Cheek and décolletage Wrinkles","Inclusion Criteria:\n\n1. Patient Informed consent form (ICF) signed;\n2. Female Subjects between 35 and 65 years old at the time of the signature of ICF;\n3. Subjects with at least 2 (shallow wrinkles) on the Lemperle Rating Scale requiring correction of cheek wrinkles and\u002For subjects requiring correction of décolletage wrinkles;\n4. Willingness to follow all study procedures, including attending all site visits, tests and examinations;\n5. Agreeing to present at each study visit without make-up;\n6. Willingness not to undergo other procedures involving aesthetic correction (e.g., ultrasound-based treatments, biomaterial implant, lifting, botulinum toxin injections, laser or intense pulsed light treatment, bio-stimulating treatment, chemical peeling, dermabrasion, fillers) during the entire study period;\n7. Willingness to follow indications to not be exposed to make-up for 12 hours after injection;\n8. Willingness to avoid prolonged exposure to sunlight and UV or using saunas or Turkish baths for one week after the injection.\n\nExclusion Criteria:\n\n* Other - different - clinical conditions of the skin (i.e. rosacea,psoriasis, vitiligo, active eczema, severe scleroderma, severe acne and diagnosticated cancer with\u002Fwithout ongoing antitumor therapy); 2. Infectious or inflammatory processes near the area of intervention; 3. Presence of naevi in the area to be injected; 4. Ongoing use or exposure to benzalkonium chloride solutions; 5. Patients who tend to develop hypertrophic scarring; 6. Patients with a history of autoimmune disease or who are receiving immune therapy; 7. Patients who are known to be hypersensitive to hyaluronic acid; 8. Presence of cutaneous disease on the tested area, as lesions, malformations and recurrent facial\u002Flabial herpes; 9. Presence of tendon, bone or muscular implants near the areaof intervention; 10. Ongoing cutaneous allergies; 11. Known hypersensitivity to cheloids; 12. Allergy or contraindications to device components; 13. Allergy or contraindication to one of the components of local anesthetic (patch or cream); 14. Immune system illnesses; 15. Diabetes mellitus or uncontrolled systemic diseases (endocrine, hepatic renal, cardiac, pulmonary, neurological disorder); 16. Problems with coagulation or undergoing anticoagulant therapy; 17. Patients who are using substances that can prolong bleeding(such as aspirin, nonsteroidal anti-inflammatory drugs, and warfarin); 18. Current treatment with anti-inflammatory drugs, anti-histaminic, topic and systemic corticosteroids, narcotic, antidepressant, immunosuppressive drugs (with the except of contraceptive or hormonal treatment starting more than 1 year ago), drugs able to influence the test results in the investigator opinion; 19. Known drug and\u002For alcohol abuse; 20. Mental incapacity that precludes adequate understanding or cooperation; 21. Any previous permanent and nonpermanent cutaneous treatment for aesthetic correction (e.g., ultrasound-based treatments, biomaterial implant, lifting, botulinum toxin injections, laser or intense pulsed light treatment, bio-stimulating treatment, chemical peeling, dermabrasion, fillers) within 6 months prior to study inclusion; 22. Active malignant neoplasm of any type, or history of a malignancy (patients with a history of other malignancies that have been surgically removed and who have no evidence of recurrence for at least five years before study enrollment are also acceptable); 23. Pregnancy or breastfeeding; 24. COVID-19 vaccination within one month prior to study inclusion; 25. Current participation in a similar study or during the previous 3 months.","35 Years","65 Years",{"count":53,"type":21},55,[55],"NA","A Post-Market, Single-arm, Confirmatory Interventional Clinical Investigation to evaluate the Performance and Safety of INNEA and INNEA AQUA for the treatment of cheek and décolletage wrinkles",[27,58],"Aging",[60,61,62],"wrinkles","aging of the skin","Innea-2022","2026-04-13",{"date":65,"type":34},"2026-04-16",{"date":67,"type":34},"2023-06-01",{"date":69,"type":21},"2026-12-30",{"name":71,"class":72},"Innate srl","INDUSTRY",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":16,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100625354","phase-4-assess-injectable-hyaluronic-acid-gel-for-the-treatment-of-volume-loss-skin-laxity-and-fine-lines-100625354","NCT07421544","Assess Injectable Hyaluronic Acid Gel for the Treatment of Volume Loss, Skin Laxity and Fine Lines","A Prospective, Phase 4, Multicenter, Open-label Pilot Study of Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid Gel for the Treatment of Volume Loss, Skin Laxity and Fine Lines","Inclusion Criteria:\n\n1. Adult subjects aged 30 to 75 years at the time of screening\u002Fbaseline.\n2. Fitzpatrick skin types I-VI.\n3. Investigator classification of the subject as having mild-to-moderate facial aging in at least one (≥1) facial areas, defined as meeting the following scale criteria at screening\u002Fbaseline:\n\n   Midface Volume Deficit Scale (Appendix A): score of 2-3 Nasolabial Folds Severity Scale (Appendix B): score of 2 or 3\n4. Willing and able to comply with all study requirements, including scheduled visits, treatment protocol, and follow-up assessments.\n5. Willing and able to provide written informed consent form and photography release for research, publication, and\u002For commercial use.\n6. In good general health as determined by the investigator based on medical history and clinical judgment.\n7. Willing to maintain the study-specified skincare regimen and refrain from initiating new topical or procedural facial treatments during the study period.\n8. For subjects of childbearing potential, a negative urine pregnancy test at screening\u002Fbaseline and at all subsequent visits, as applicable.\n9. Female subjects of childbearing potential must agree to use an acceptable method of contraception throughout the study and must have been using systemic contraception consistently for at least 30 days prior to enrollment, unless they meet criteria for non-childbearing potential.\n\nSubjects are considered not of childbearing potential if they meet one of the following:\n\nHistory of hysterectomy or bilateral oophorectomy, or No menses for at least 12 consecutive months without an alternative medical cause.\n\nOr, if of childbearing potential, must agree to use an effective form of contraception during the course of the study. Acceptable methods include:\n\nOral contraceptive pill, injection, implant, patch, vaginal ring, or intrauterine device (IUD) Intrauterine coil Bilateral tubal ligation Hysterectomy Barrier method used with an additional form of contraception (e.g., spermicide, sponge, or condom) Abstinence (must agree to use a barrier method if sexual activity begins during the study) Partner with a vasectomy (if not, subject must agree to use a barrier methods\n\nExclusion Criteria:\n\n1. Prior use of injectable treatments to the face within the past 12 months, including HA fillers and biostimulator injectables, i.e. calcium hydroxyapatite, poly-L-lactic acid (e.g., Sculptra, Radiesse), platelet-rich plasma (PRP), platelet-rich fibrin (PRF) Any facial surgical procedure (e.g., facelift, facial implants) within the past 12 months.\n2. Use of neuromodulators (e.g., botulinum toxin) to the face or neck within 6 months prior to study enrollment or at any time during the study period.\n3. Use of dermal fillers of any kind during the study period.\n4. Use of at-home energy-based devices intended for rejuvenation or fibroblastic\u002Fcollagen stimulation within 30 days prior to treatment and during the study period.\n5. Use of systemic retinoids (e.g., isotretinoin) within 3 months prior to enrollment\n6. Active infection, open wounds, or inflammatory dermatoses (e.g., eczema, psoriasis, dermatitis) in the treatment area.\n7. Plants to become pregnant during the study period, or current breastfeeding.\n8. Known allergy or hypersensitivity to lidocaine, tetracaine, or other local anesthetics.\n9. Coagulation disorders or use of anticoagulants or antiplatelet medications that cannot be safely discontinued per investigator discretion.\n10. History of autoimmune connective tissue diseases (e.g., systemic lupus erythematosus, scleroderma, dermatomyositis).\n11. Current or recent use (within the past 3 months) of systemic immunosuppressive medications.\n12. Any uncontrolled systemic condition that may increase risk or interfere with study participation, including but not limited to poorly managed diabetes, thyroid dysfunction, or cardiovascular disease.\n13. Clinically significant neurological, psychological or psychiatric conditions, or any condition that, in the opinion of the investigator, may interfere with study participation or interpretation of results.\n14. Current use of tobacco or nicotine-containing products, or use within 6 months prior to enrollment; participants must also agree to abstain from tobacco and nicotine-containing products for the duration of the study.\n15. Participation in any other interventional clinical study within 30 days prior to enrollment or during the course of this study.\n16. Unwillingness to refrain from undergoing any additional aesthetic treatments to the face and neck (e.g., lasers, injectables, energy-based devices, cosmeceuticals, etc.) from screening through the end of the study period.\n17. Use of sunless tanner or have spray tanned in the treatment areas 4 weeks prior to study treatment.\n18. History of keloids or scarring\u002Ftattoos in the treatment area.","ALL","30 Years","75 Years",{"count":84,"type":21},100,[24],"Clinical trial to assess the real-world effectiveness of Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid (HA) gel for the treatment of mild-to-moderate facial aging, including volume loss, fine lines, and skin laxity, following treatment administered using routine clinical injection techniques over the course of 60 days.",[88,27,89,90],"Fine Lines","Facial Laxity","Volume Loss","NOT_YET_RECRUITING","2026-02-12",{"date":94,"type":34},"2026-02-19",{"date":96,"type":21},"2026-03-01",{"date":98,"type":21},"2026-07-01",{"name":100,"class":41},"Goldman, Butterwick, Fitzpatrick and Groff",1,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":80,"minAge":18,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":113,"conditions":114,"keywords":117,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":101},"100541913","pre-marketing-trial-to-assess-safety-and-efficacy-of-volumizing-filler-based-on-hyaluronic-acid-and-recombinant-collagen-100541913","NCT06336044","Pre-marketing Trial to Assess Safety and Efficacy of 'Volumizing Filler Based on Hyaluronic Acid and Recombinant Collagen'","\"Clinical and Instrumental Evaluation of the Safety and Bio-revitalizing Effect on the Face of the Medical Device 'Volumizing Filler Based on Hyaluronic Acid and Recombinant Collagen'\"","Inclusion Criteria:\n\n* all sexes\n* caucasic\n* 18 to 70 years\n* non smoker\n\nExclusion Criteria:\n\n* Pregnancy\n* milking\n* smoker\n* alcohol or drugs abuse\n* change of BMI during the study\n* previous facial surgery, implants, permanent treatments\n* sensitivity to the product\n* dermatological difficult frame\n* health weakness\n* treated with anticoagulants, antihistaminics, corticosteroids, antidepressants and other drugs impacting on the results","70 Years",{"count":111,"type":21},40,[55],"Study to validate the safety and efficacy of the Hyaluronic Acid +Collagen filler 40 patients will undergo through 3 visits one to asses the health and apply the filler one after 4 weeks to check the results one after 16 weeks for the final check and results validation Safety assessed with analysis of the Adverse Events",[27,115,116],"Scar","Laxity; Skin",[118,119,120,121],"hyaluronic acid","Collagen","Filler","Wrinkles","2026-01-22",{"date":124,"type":34},"2026-01-26",{"date":126,"type":21},"2026-02",{"date":128,"type":21},"2026-06",{"name":130,"class":72},"Taumedika s.r.l.",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":16,"sex":80,"minAge":81,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":141,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":101},"100607341","a-prospective-controlled-study-to-evaluate-the-safety-and-effectiveness-of-thermage-flx-radiofrequency-treatment-100607341","NCT07187297","A Prospective Controlled Study to Evaluate the Safety and Effectiveness of Thermage® FLX Radiofrequency Treatment","A Prospective Controlled Study to Evaluate the Safety and Effectiveness of Thermage® FLX Radiofrequency Treatment to Improve Lines and Wrinkles and to Lift and Tighten Lax Tissue in the Neck, Abdomen, Upper Arms, and Face","Inclusion Criteria:\n\n* Be an adult female or male, ≥30 - ≤60 years of age.\n\nHave mild-to-moderate skin laxity of the neck, abdomen, upper arms, and\u002For face, and\u002For mild-to-moderate lines and\u002For wrinkles of the neck and\u002For face assessed as follows:\n\nNeck:\n\nMild-to-moderate neck skin laxity as defined by a score of 1 to 6 on the 10-point Facial Laxity Rating Scale (scored 0-9)\n\nMild-to-moderate neck wrinkles as defined by a score of 1 to 6 on the 10-point Fitzpatrick Wrinkle Scale (scored 0-9)\n\nAbdomen:\n\nMild-to-moderate abdomen skin laxity as defined by a score of 1 or 2 on a 4-point Abdominal Laxity Scale (scored 0-3)\n\nUpper arms:\n\nMild to moderate upper arms skin laxity as defined by grade 2 or 3 on the 5-grade IBSA Inner Upper Arm Laxity Scale\n\nFace:\n\nMild-to-moderate facial skin laxity as defined by a score of 1 to 6 on the 10-point Facial Laxity Rating Scale (scored 0-9)\n\nMild-to-moderate facial wrinkles as defined by a score of 1 to 6 on the 10-point Fitzpatrick Wrinkle Scale (scored 0-9)\n\nFemales of childbearing potential must have a negative urine pregnancy test. Females who have experienced menarche and who are not postmenopausal (either confirmed via FSH testing or who have not menstruated for 2 years or more without an alternative medical cause) or surgically sterile will be considered of childbearing potential.\n\nFemales of childbearing potential must agree to use an acceptable method of birth control for the duration of the study. Acceptable methods of birth control are oral and other systemic contraceptives, condoms only, intrauterine device, double-barrier methods, bilateral tubal ligation, partner vasectomy, and abstinence.\n\nHave no clinically abnormal findings based on the medical history as determined by the study investigator.\n\nBe able to follow the study instructions, be available on the specific required study visit days, and be willing to complete all study visit procedures and assessments.\n\nUnderstand the research nature of this study and sign an informed consent document prior to the performance of any study-specific procedure or assessment.\n\nAgree to not undergo excluded procedures (i.e., energy-based device treatments, injectables, or plastic surgery) on the study treatment areas for the duration of study.\n\nParticipant has a body mass index (BMI) ≤30.\n\nExclusion Criteria:\n\n* Participant is pregnant or breast feeding or trying to become pregnant for 3 months prior to the screening visit or during the study.\n\nParticipant has given birth within 3 months prior to the screening visit.\n\nParticipant has an anticipated need for procedures, surgery, overnight hospitalization, or other events that would prevent the participant from making the required visits during the study.\n\nParticipant has a pacemaker, internal defibrillator, or other implanted electronic device.\n\nParticipant has an implant in the target treatment zone(s).\n\nParticipant has had radiation therapy in the target treatment zone(s).\n\nParticipant has had 1 or more prior cosmetic procedures in the target treatment zone(s) including:\n\nThermage or any energy-based device procedure, derm abrasion, or chemical peel on any treatment area within 6 months prior to the screening visit.\n\nShort-acting neurotoxins within 6 months prior to the screening visit.\n\nLong-acting neurotoxins within 9 months prior to the screening visit.\n\nHyaluronic acid filler ≤1 year prior to the screening visit.\n\nSemi-permanent or permanent fillers at any time prior to the screening visit.\n\nPlastic surgery within 1 year prior to the screening visit.","60 Years",{"count":140,"type":21},164,[55],"A prospective, 180-day, randomized, multicenter, independent blinded evaluators, controlled study of treatment with the Thermage FLX System",[27,144,145],"Lax Skin","Lines Skin","2025-12-15",{"date":148,"type":34},"2025-12-17",{"date":150,"type":34},"2025-10-31",{"date":152,"type":21},"2027-03",{"name":154,"class":72},"Bausch Health Americas, Inc.",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":16,"sex":17,"minAge":162,"maxAge":163,"enrollmentInfo":164,"targetDuration":4,"studyType":22,"phases":166,"briefSummary":168,"conditions":169,"keywords":170,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":101},"100609967","phase-2-assess-impact-of-microdroplet-hyaluronic-acid-filler-on-skin-quality-in-patients-on-glucagon-like-peptide-1-agonists-100609967","NCT07221461","Assess Impact of Microdroplet Hyaluronic Acid Filler on Skin Quality in Patients on Glucagon-like Peptide-1 Agonists","Prospective, Single Center, Open-label Study Assessing Impact of Microdroplet Hyaluronic Acid Filler on Skin Quality and Biomarkers in Patients on Glucagon-like Peptide-1 Agonists","Inclusion Criteria:\n\n1. Adult women aged 25-50 years.\n2. Fitzpatrick skin types I-VI.\n3. Current treatment with a stable dose of GLP-1 agonist medication for at least the last 6 months, for 16 of the enrolled subjects. Remaining 8 subjects should not be taking or have a history of taking a GLP-1 agonist therapy in the last year.\n4. Presence of moderate skin changes (as defined by Modified Griffiths' Scale, with an average score of 4-6) in the following criteria: skin radiance\u002Fbrightness, skin elasticity, tone evenness, skin firmness, fine lines, global wrinkles, and skin smoothness (tactile and visual).\n5. Participants must maintain a stable weight, defined as no greater than a 10% weight change from screening\u002Fbaseline and throughout the study.\n6. Participants must have a body mass index (BMI) of 27 or less.\n7. Must be willing to sign a photography release and ICF, and complete the entire course of the study.\n8. Participant must agree to maintaining the same skincare routine they are currently using throughout the study period.\n9. Subjects in good general health based on investigator's judgment and medical history.\n10. Negative urine pregnancy test result at the time of study entry (if applicable).\n11. Females of childbearing potential must be willing to use an acceptable method of birth control during the entire course of the study. All systemic birth control measures must be in consistent use for at least 30 days prior to study enrollment.\n\n    1. 1\\. Acceptable methods of birth control are: oral contraceptive pill, injections, implants, patches, vaginal rings, intrauterine device\u002Fcoil, double-barrier methods (e.g., sponge, spermicide, or condoms). Abstinence and\u002For vasectomized partner must agree to a second acceptable method of birth control (double-barrier) should the subject become sexually active.\n    2. 2\\. A female is considered of non-childbearing potential if she is: postmenopausal (no menses for at least 12 months), without a uterus (hysterectomy) and\u002For both ovaries (oophorectomy), or bilateral tubal ligation.\n\nExclusion Criteria:\n\n1. The presence of severe facial skin aging (as defined by Modified Griffiths' Scale, with an average score of 7-9) or minimal facial skin aging (as defined by Modified Griffiths' Scale, with an average score of 0-3).\n2. Females who are pregnant, planning a pregnancy, or currently breast feeding during the study.\n3. Any uncontrolled systemic disease.\n4. History of autoimmune connective tissue disease.\n5. Current use of immunosuppressive medication.\n6. Weight change of greater than 10% during the study period.\n7. Significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study.\n8. Active dermatitis (including but not limited to atopic dermatitis, psoriasis, rosacea, acne, melasma, etc.), active infections, or other skin condition in the proposed treatment area that in the investigator's opinion might interfere with the evaluation of study parameters.\n9. Mesotherapy; dermal fillers, biostimulator injectables; radiofrequency device treatments; microfocused ultrasound device treatments; laser and light-based device treatments; microneedling; cryolipolysis; high intensity focused electromagnetic energy device treatment; or surgery during the 12-month period before study treatment. Botulinum toxin injections (Botox, Dysport, Xeomin, Daxify, Jeuveau) during the 6-month period before study treatment.\n10. Any investigational treatment for skin quality of the cheeks during the 12-month period before the study treatment.\n11. Creams\u002Fcosmeceuticals and\u002For home therapies for the prevention or treatment of skin fine lines, wrinkles, radiance, elasticity, firmness, or smoothness in the treatment area during the 4-week period before study treatment and throughout the course of the study.\n12. Subjects with scarring in the treatment areas. Subjects with a history of keloids will be excluded.\n13. Subjects who spray tanned or used sunless tanners in the treatment areas 4 weeks prior to study treatment.\n14. History of bleeding disorder, concomitant use of anticoagulants, history of connective tissue disease (e.g., lupus, scleroderma), history of Bell's Palsy, epilepsy, smoking, and\u002For current pregnancy or breastfeeding.\n15. Inability to ambulate following the procedure.\n16. History of lidocaine and\u002For tetracaine sensitivity deemed by the investigator to preclude subject from enrolling into study.\n17. Individuals with known allergies or sensitivities to any of the ingredients of any topical or injectable products being used in this study.\n18. Subjects planning any cosmetic procedure to the treatment area during the study period, other than the treatment that will be performed by the investigator.\n19. Use of topical steroids, retinoids\u002Fretinols, or vitamin C to the face within the previous 2-weeks of screening.\n20. Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.","25 Years","50 Years",{"count":165,"type":21},24,[167],"PHASE2","Clinical trial to assess the effect of microdroplet hyaluronic acid filler to the cheek skin (SKINVIVE™, JUVÉDERM®, Irvine, CA) on skin quality in patients undergoing medical weight loss with GLP-1 therapy.",[27],[171,172,173,174],"skin laxity","fine lines","dull skin","uneven skin tone","2025-10-24",{"date":177,"type":34},"2025-10-28",{"date":179,"type":21},"2025-11-01",{"date":181,"type":21},"2026-03-02",{"name":100,"class":41},{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":16,"sex":80,"minAge":18,"maxAge":109,"enrollmentInfo":189,"targetDuration":4,"studyType":22,"phases":191,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":101},"100582846","avava-miria-general-use-100582846","NCT06868615","AVAVA MIRIA General Use","Inclusion Criteria:\n\n1. Male or female subjects between 18 to 70 years of age.\n2. Dermatologic condition that can be addressed by the laser, including but not limited to:\n\n   1. Wrinkles\n   2. Scars\n   3. Acne Scars\n   4. Active Acne\n   5. Dyschromia\n   6. Cutaneous Lesions such as Age or Sun Spots\n   7. Melasma\n   8. Laxity\n3. Willingness to have digital photographs taken of treatment area(s) and agreement with use of photographs for presentation, educational, or marketing purposes.\n4. Willingness to comply with the following during the study, including the follow-up period:\n\n   1. maintain consistent skin care regimen on treated areas.\n   2. cover treated areas or have very limited sun exposure and, if requested, use an approved sunscreen of SPF 50 or higher.\n   3. refrain from using systemic corticosteroids, according to Investigator discretion.\n   4. refrain from using topical corticosteroids, retinoids, or prescription skin-lightening medications on the treated areas, according to Investigator discretion.\n   5. refrain from any other procedures in the treatment areas.\n5. Willingness and ability to comply with study instructions and return for required visits.\n6. Subject has read and signed a written informed consent form.\n7. Subject lives within 50 miles of study site.\n8. Willingness to shave hair in intended treatment area\n\nExclusion Criteria:\n\n1. Skin pathology or condition that could interfere with evaluation of the study procedure, e.g.,\n2. Systemic treatment prescribed within previous 6 months (e.g., oral medication such as isotretinoin)\n3. Surgical treatment in the target areas within previous 6 months (e.g., laser surgery)\n4. Active vitiligo, psoriasis, or eczema in the treatment area\n5. Injection of dermal filler in the target areas within previous 1 month (e.g., collagen, hyaluronic acid filler)\n6. Cosmetic procedures in the target areas within prior 3 months (e.g., laser, microdermabrasion, skin peel)\n7. Topical treatment applied to target areas within the previous 1 month or according to Investigator discretion.\n8. Active suntan and unable or unlikely to refrain from tanning within the follow-up period.\n9. Artificial tanning in the target areas within the previous 1 month (e.g., spray, lotion, tanning bed) or intention to use artificial tanning within the follow-up period.\n10. Active localized or systemic infection, or an open wound in area being treated.\n11. Lesions in the treatment areas suspicious for malignancy (skin cancer, melanoma)\n12. History of abnormal wound healing or abnormal scarring (e.g., hypertrophic or keloid)\n13. History of connective tissue disease, such as lupus or scleroderma.\n14. Any use of medication that is known to increase sensitivity to light according to Investigator's discretion (e.g., topicals that produce sensitivity to light may be used in areas other than the target area).\n15. History of gold therapy.\n16. History of disease stimulated by heat, such as recurrent herpes simplex or herpes zoster (shingles) in the treatment area, unless treatment is conducted following a prophylactic regimen.\n17. History of radiation to the treatment area or currently undergoing systemic chemotherapy for the treatment of cancer.\n18. For Female: Pregnancy or lactation, or intent to become pregnant within the study period.\n19. Significant uncontrolled concurrent illness, such as diabetes mellitus or cardiovascular disease, e.g., uncontrolled hypertension.\n20. History of immunosuppression\u002Fimmune deficiency disorder or currently using immunosuppressive medications.\n21. Current enrollment in a clinical study of any other unapproved investigational drug or device\n22. Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect response or participation in this clinical study, or would pose an unacceptable risk to the subject.",{"count":190,"type":21},200,[55],"A general protocol to treat a variety of dermatologic conditions and collect patient feedback.\n\nPrimary outcome is the collection and analysis of patient questionnaires related to the overall experience of the device treatment. Secondary outcome measures include physician and subject evaluations in regards to improvement seen in the device as well as assessment of side effects.",[194,195,196,27,197,198],"Acne","Acne Scars - Mixed Atrophic and Hypertrophic","Scars","Pigment; Lesion","Skin Texture Disorder","2025-03-06",{"date":201,"type":34},"2025-03-11",{"date":203,"type":34},"2024-09-11",{"date":205,"type":21},"2027-12-30",{"name":207,"class":72},"AVAVA, Inc.",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":22,"phases":217,"briefSummary":218,"conditions":219,"keywords":224,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":101},"100560021","the-effects-of-topical-almond-oil-and-tretinoin-on-facial-wrinkles-100560021","NCT06571721","The Effects of Topical Almond Oil and Tretinoin on Facial Wrinkles","Prospective, Double-Blinded, Randomized Study of Topical Almond Oil and Tretinoin on Facial Wrinkles","Inclusion Criteria:\n\n* Post-menopausal women of Fitzpatrick skin types 1, 2, and 3\n* Individuals with facial fine lines and wrinkles\n\nExclusion Criteria:\n\n* Individuals who are pregnant or breastfeeding\n* Prisoners\n* Adults unable to consent\n* Those with a nut allergy or tocopherol allergy\n* Current smokers, those that have smoked within the past year, and former smokers with greater than a 10-pack- year history of smoking\n* Those with an autoimmune photosensitive condition or a known genetic condition with a deficiency in collagen production (such as Ehlers-Danlos syndromes)\n* Those who have undergone any cosmetic procedures to the face in the 3 months prior to enrollment in the opinion of the investigator. People that have undergone deeper chemical peels (TCA based peels) within 1 year prior to enrollment\n* Individuals who are unwilling to discontinue vitamin E containing supplements and food sources such as all nuts, sunflower seeds or sunflower oil during the washout and intervention\n* Individual who are unwilling to discontinue topical cosmetic products during the duration of the study or unwilling to undergo a 2-week washout of topicals that are known to modulate collagen and pigment:\n* Retinoids such as tretinoin, adapalene, retinol, except as provided by the study.\n* Antioxidant ingredients such as vitamin C or vitamin E.\n* Pigment reducing agents such as hydroquinone, azelaic acid, kojic acid, or a retinoid except for the retinol that is provided in this study.\n* Topicals that contain a nut oil or nut extract as part of their ingredient list.",{"count":216,"type":21},90,[55],"Investigate the topical use of almond oil, almond oil augmented with 0.5% vitamin E, 0.025% tretinoin oil augmented with castor oil on the appearance of facial fine lines and wrinkles, pigmentation, hydration, trans-epidermal water loss, and sebum excretion rate.",[220,27,221,222,223],"Collagen Degeneration","Pigmentation","Elastic Skin","Sebum Deficiency",[225,226,227,221],"Facial Wrinkles","Skin biophysical properties","Photoaging","2024-08-26",{"date":230,"type":34},"2024-08-28",{"date":232,"type":34},"2024-07-22",{"date":234,"type":21},"2025-07-22",{"name":236,"class":72},"Integrative Skin Science and Research",{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":16,"sex":80,"minAge":163,"maxAge":51,"enrollmentInfo":244,"targetDuration":4,"studyType":22,"phases":246,"briefSummary":247,"conditions":248,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":4},"100553487","efficacy-and-safety-of-675-nm-laser-for-dorsal-hand-rejuvenation-100553487","NCT06486727","Efficacy and Safety of 675-nm Laser for Dorsal Hand Rejuvenation","Efficacy and Safety of 675-nm Laser for Dorsal Hand Rejuvenation in Thai Patients","Inclusion Criteria:\n\n* Subjects diagnosed with wrinkles and solar lentigines on both dorsum of hands\n\nExclusion Criteria:\n\n* Pregnant or lactation\n* Sugjects with a history of allergy to near-infrared wavelength or photosensitizing agents\n* Subjects who have been treated with any kind of energy-based device on both dorsum of hands 6 months prior to the inclusion\n* Subjects who have been injected with filler, or platelet-rich plasma on both dorsum of hands on their faces 6 months prior to the inclusion\n* Active skin infections\n* History of hypertrophic scars or keloids",{"count":245,"type":21},26,[55],"This study aimed to evaluate efficacy and safety of 675-nm laser for dorsal hand rejuvenation in Thai patients. Twenty-six subjects aged 50 to 65 years diagnosed with wrinkle and solar lentigines on both dorsums of hands were included and treated with RedTouch for 3 times every 4 weeks. Then, they were follow up at 3 and 6 months after the final treatment. The measurement of 5-point Global Aesthetic Improvement Scale scores by physicians and subjects were conducted. Moreover, pigmentation level, wrinkle and texture were also recored using Antera. Elasticity was measured using Cutometer.",[27],"2024-07-05",{"date":251,"type":34},"2024-07-08",{"date":253,"type":21},"2024-07-01",{"date":255,"type":21},"2025-12-01",{"name":257,"class":41},"Mahidol University",{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":16,"sex":17,"minAge":50,"maxAge":109,"enrollmentInfo":265,"targetDuration":4,"studyType":22,"phases":267,"briefSummary":268,"conditions":269,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":101},"100521798","the-effects-of-almond-on-facial-skin-collagen-and-wrinkles-100521798","NCT06074276","The Effects of Almond on Facial Skin Collagen and Wrinkles","Prospective Randomized Controlled Trial on the Effects of Almond on Facial Skin Collagen and Wrinkles","Inclusion Criteria:\n\n* Subjects 35 to 70 years of age of all skin types\n* 50% of the subjects will be postmenopausal women determined as \\>1-year loss of menstrual period\n* 50% of the subjects will be premenopausal women\n* BMI 18.5 - 35 kg\u002Fm2\n* Individuals with a habitual diet that has been maintained for at least 6 months and to be maintained for the duration of the study\n* Individuals must maintain their usual skincare products, defined as products that has been used for at least 1 month, for the duration of the study\n\nExclusion Criteria:\n\n* Those with a nut allergy\n* Those who are unwilling to discontinue oral collagen supplementation 1 month prior to the start of the study\n* Individuals who are unwilling to discontinue vitamin E or nut containing supplements 2 weeks prior to and during the intervention.\n* Individuals who are pregnant or breastfeeding\n* Change in skincare products during the study\n* Had a medical or cosmetic procedure such as laser resurfacing or plastic surgery to the face within the last 6 months (include botulinum toxin, dermal fillers, collagen, or other similar cosmetic procedure)\n* Has an autoimmune photosensitive condition or known genetic condition with a deficiency in collagen production (such as Ehler-Danlos)\n* Those with a skin disease on their face that would affect the assessment of their skin based on the assessment of the investigator.\n* Current tobacco smoker or a tobacco smoking history of greater than 10 pack-years",{"count":266,"type":21},60,[55],"Investigate the effects of almond consumption on collagen production, elastin levels, wrinkles, and pigmentation among premenopausal women and postmenopausal women belonging to all Fitzpatrick skin types.",[220,27,221,222],"2024-06-15",{"date":272,"type":34},"2024-06-18",{"date":274,"type":34},"2023-10-04",{"date":276,"type":21},"2024-12-31",{"name":236,"class":72},{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":80,"minAge":284,"maxAge":51,"enrollmentInfo":285,"targetDuration":4,"studyType":287,"phases":4,"briefSummary":288,"conditions":289,"keywords":290,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":300},"100545689","assessing-the-impact-of-botulinum-toxin-type-a-on-facial-wrinkles-a-comprehensive-clinical-investigation-100545689","NCT06385171","Assessing the Impact of Botulinum Toxin Type A on Facial Wrinkles: A Comprehensive Clinical Investigation","Inclusion Criteria:\n\n* Individuals of both genders.\n* Must be in good physical health.\n* Age between 20 and 65 years.\n* Presence of both static (unchanging) and moderate dynamic (movement-induced) wrinkles on the forehead or glabellar region.\n* Must possess the willingness and ability to understand and provide informed consent, as well as effectively communicate with study personnel.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding female.\n* Age below 20 or above 65 years.\n* History of neuromuscular disorders, such as myasthenia gravis.\n* History of facial surgery or presence of scars in the treatment area that could potentially interfere with or confound the results of the study.\n* Recent treatment history within the past 6 months in the forehead or glabellar region, including:\n* Ablative laser procedures.\n* Radiofrequency device treatments.\n* Ultrasound device treatments.\n* Medium to deep chemical peels.\n* Temporary soft tissue augmentation.\n* Semi-permanent soft tissue augmentation within the past 2 years.\n* Permanent soft tissue augmentation.\n* Planned cosmetic procedures within the next 6 months in the same region.\n* Intended use of tretinoin or retinoic acid within the next 6 months.\n* Presence of active infection in the treated area, excluding mild acne.\n* Allergy to cow's milk protein or albumin.\n* Use of aminoglycoside medications.\n* Current use of anticoagulation therapy.\n* History of bleeding disorders.\n* Diagnosis of mental illness.\n* Inability to comprehend the study protocol or provide informed consent.","20 Years",{"count":286,"type":21},500,"OBSERVATIONAL","A study conducting to see how well a treatment called Botulinum Toxin Type A works for reducing facial wrinkles. The study will help us understand if this treatment is safe and effective for making wrinkles on the face less noticeable.",[27],[225],"2024-05-23",{"date":293,"type":34},"2024-05-24",{"date":295,"type":34},"2024-05-22",{"date":297,"type":21},"2027-01-05",{"name":299,"class":41},"Global Aesthetics LLC",2,{"id":302,"slug":303,"hasResults":11,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":4,"eligibilityCriteria":307,"healthyVolunteers":16,"sex":80,"minAge":308,"maxAge":109,"enrollmentInfo":309,"targetDuration":4,"studyType":22,"phases":311,"briefSummary":312,"conditions":313,"keywords":314,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":326},"100346639","study-to-evaluate-the-safety-and-efficacy-of-the-cytrellis-micro-coring-device-for-the-treatment-of-moderate-to-severe-facial-wrinkles-100346639","NCT03793348","Study to Evaluate the Safety and Efficacy of the Cytrellis Micro-Coring Device for the Treatment of Moderate to Severe Facial Wrinkles","A Prospective, Multi-center, Pivotal Study to Evaluate the Safety and Efficacy of the Cytrellis Micro-Coring Device for the Treatment of Moderate to Severe Facial Wrinkles","Inclusion Criteria:\n\n* Males and females 40-70 years of age\n* Fitzpatrick Skin Type I to IV as judged by the Investigator\n* Cheek areas are at least a score of 3 using the Lemperle Wrinkle Assessment Scale as judged by the Investigator\n* Able to provide written informed consent, understand and willing to comply with all study related procedures and follow-up visits.\n\nExclusion Criteria:\n\n* Lesions suspicious for any malignancy or the presence of actinic keratosis, melasma, vitiligo, cutaneous papules\u002Fnodules or active inflammatory lesions in the areas to be treated\n* History of keloid formation or hypertrophic scarring\n* History of trauma or surgery to the treatment areas in the past 6 months\n* Scar present in the areas to be treated\n* Silicone injections in the areas to be treated\n* Injection of dermal fillers, fat or botulinum toxin, as well as any minimally invasive\u002Finvasive medical device for skin treatment, in the study treatment areas, within the past 6 months (i.e., dermabrasion, laser, RF devices)\n* Active smokers (0.5 pack\u002Fday) or having quit within 3 months prior to treatment\n* Active, chronic, or recurrent infection\n* History of compromised immune system or currently being treated with immunosuppressive agents\n* History of sensitivity to analgesic agents, Aquaphor®, topical or local anesthetics (e.g., lidocaine, benzocaine, procaine) or chlorhexidine, povidone-iodine or epinephrine\n* Excessive sun exposure and use of tanning beds or tanning creams within 30 days prior to treatment\n* Treatment with aspirin or other blood thinning agents within 14 days prior to treatment\n* History or presence of any clinically significant bleeding disorder\n* Any issue that, at the discretion of the Investigator, would interfere with assessment of safety or efficacy or compromise the subject's ability to participate in the study\n* Treatment with an investigational device or agent within 30 days before treatment or during the study period","40 Years",{"count":310,"type":21},35,[55],"Study evaluating the efficacy of a micro coring device for the treatment of moderate to severe check wrinkles",[27],[315,171,316],"facial wrinkles","sagging skin","2019-01-02",{"date":319,"type":34},"2019-01-04",{"date":321,"type":34},"2018-11-12",{"date":323,"type":21},"2019-08-21",{"name":325,"class":72},"Cytrellis Biosystems, Inc.",6]